Which agent is used for smoking cessation but is not a cholinergic (direct-acting) agonist?

Which agent is used for smoking cessation but is not a cholinergic (direct-acting) agonist?

• A. Pilocarpine
• B. Methacholine
• C. Varenicline
• D. Demecarium

Answer: (C)

Varenicline works for smoking cessation by targeting brain nicotinic receptors rather than acting as a traditional cholinergic agonist in the body. It is a partial agonist at alpha4beta2 nicotinic acetylcholine receptors in the CNS. By partially stimulating these receptors, it helps ease withdrawal, and by occupying the receptor, it blocks nicotine from binding, reducing the rewarding effect of smoking. This dual action addresses both withdrawal and reinforcement without activating muscarinic receptors in the rest of the body, so it avoids typical cholinergic side effects associated with direct-acting muscarinic agonists or indirect cholinergic enhancers. The other agents listed act through classic cholinergic mechanisms: direct muscarinic agonists stimulate muscarinic receptors (causing peripheral cholinergic effects), and an acetylcholinesterase inhibitor increases acetylcholine levels to enhance cholinergic activity. Those mechanisms are not how smoking cessation is achieved, which is why they are not the best choice for this purpose.

Varenicline works for smoking cessation by targeting brain nicotinic receptors rather than acting as a traditional cholinergic agonist in the body. It is a partial agonist at alpha4beta2 nicotinic acetylcholine receptors in the CNS. By partially stimulating these receptors, it helps ease withdrawal, and by occupying the receptor, it blocks nicotine from binding, reducing the rewarding effect of smoking. This dual action addresses both withdrawal and reinforcement without activating muscarinic receptors in the rest of the body, so it avoids typical cholinergic side effects associated with direct-acting muscarinic agonists or indirect cholinergic enhancers.

The other agents listed act through classic cholinergic mechanisms: direct muscarinic agonists stimulate muscarinic receptors (causing peripheral cholinergic effects), and an acetylcholinesterase inhibitor increases acetylcholine levels to enhance cholinergic activity. Those mechanisms are not how smoking cessation is achieved, which is why they are not the best choice for this purpose.